Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy.
Amodiaquine (AQ) is an antimalarial drug that was frequently combined with artesunate (AS) for the treatment of uncomplicated malaria due to Plasmodium falciparum and is now available as a fixed-dose combination. Despite its widespread use, the simultaneous pharmacokinetics in patients of AQ and its active metabolite, desethylamodiaquine (DAQ), were not characterized to date. The pharmacokinetics of AQ and DAQ in 54 adult patients receiving the AS/AQ combination were therefore investigated by the use of a population approach. AQ followed a 1-compartment model with first-order absorption and elimination, as well as a first-order and irreversible transformation into DAQ, which in turn followed a 2-compartment model with first-order elimination from its central compartment. The mean AQ apparent clearance and distribution volume were 3,410 liters/h and 39,200 liters, respectively. The mean terminal elimination half-life of DAQ was 211 h. Body weight was found to explain the interindividual variability of the apparent volume of distribution of AQ and the elimination rate constant of DAQ. A new dosage form consisting of a fixed-dose combination of AS and AQ was found to have no effect on the pharmacokinetic parameters of AQ and DAQ. All patients achieved parasite clearance within 4 days following the initiation of the treatment, which prevented investigation of the possible relationship between DAQ exposure and treatment outcome. This study provided the first simultaneous pharmacokinetic model for AQ and DAQ.
Jullien
Vincent
V
Drugs for Neglected Diseases initiative, Geneva, Switzerland.
Ogutu
Bernhards
B
Juma
Elizabeth
E
Carn
Gwenaelle
G
Obonyo
Charles
C
Kiechel
Jean-René
JR
D000293:Adolescent; D000328:Adult; D000655:Amodiaquine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D000962:Antimalarials / Q000493:pharmacokinetics* / Q000494:pharmacology*; D037621:Artemisinins / Q000493:pharmacokinetics* / Q000494:pharmacology*; D004338:Drug Combinations; D005260:Female; D006207:Half-Life; D006801:Humans; D007630:Kenya; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000378:metabolism / Q000469:parasitology; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D016896:Treatment Outcome; D055815:Young Adult
D000962:Antimalarials; D037621:Artemisinins; D004338:Drug Combinations; C515299:amodiaquine, artesunate drug combination; D000655:Amodiaquine; C047386:desethylamodiaquine